<DOC>
	<DOCNO>NCT02297386</DOCNO>
	<brief_summary>The purpose study test ability new PET scan radiotracer , call FDHT ( stand [ 18F ] Dihydro-Testosterone ) , good find monitor prostate cancer . Radiotracers type drug carry small amount radioactivity see PET scanner . FDHT radiotracer look protein present almost prostate cancer cell . The investigator want find find monitor change cancer use FDHT PET scan .</brief_summary>
	<brief_title>18F Dihydro-testosterone Pet MR Imaging In Patients With Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Dihydrotestosterone</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male age 21 year old 80 year age . Signed write informed consent willingness comply protocol requirement . Histologically confirm diagnosis prostate cancer . Staging image workup include baseline MRI prostate pelvis perform MSKCC . Baseline image rule distant metastatic disease ( 99mTc bone scan , NaF PET , total body MRI , CT chest/abdomen/pelvis ) Karnofsky performance status ≥ 70 Clinical criterion require eligible : . One follow i.Pretreatment PSA ≥10 ng/dL , OR ii . Clinical Tstage assess digital rectal exam ≥T2a , OR ii . Radiographic ≥T3a MRI , OR iv . Gleason score ≥3+4=7 c. Visible intraprostatic tumor focus ≥1 cm large dimension T2weighted image base initial pretreatment MRI Physician recommendation ADT . Metastatic disease standard stag imaging ( beyond regional lymph node involvement ) . Absence metastatic disease ( beyond regional lymph node involvement ) define negative bone scan , NaF PET , CT chest/abdomen/pelvis , total body MRI . Prior treatment prostate gland malignant condition ( surgery , cryotherapy , radiotherapy , photodynamic therapy ) . Physician prescription androgen receptor antagonist therapy ( example : bicalutamide , flutamide , enzalutamide ) time protocol scan . Note : ADT consist chemical castration ( i.e . degarelix ) remove endogenous DHT . Androgen receptor antagonist bind androgen receptor inhibit FDHT binding . Patients receive testosterone supplementation . Any contraindication baseline MRI base departmental MR questionnaire , inability cooperate MRI scan . History allergic reaction attribute compound similar chemical biologic composition FDHT . Hepatic laboratory value : 1 . Bilirubin &gt; 1.5 x ULN ( institutional upper limit normal ) 2 . AST/ALT &gt; 2.5 x ULN 3 . Albumin &lt; 2 g/dL Creatinine &gt; 2.5 mg/dL Calcium &gt; 11 mg/dL Other serious illness ( e ) might preclude completion study interfere determination causality adverse effect experience study .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>[ 18F ] Dihydro-testosterone</keyword>
	<keyword>PET Scan</keyword>
	<keyword>MRI</keyword>
	<keyword>14-185</keyword>
</DOC>